<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565461</url>
  </required_header>
  <id_info>
    <org_study_id>ELT203</org_study_id>
    <nct_id>NCT00565461</nct_id>
  </id_info>
  <brief_title>LT Vaccine Patch Self-Administration Study</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label Study to Compare the Immunogenicity and Safety of a Self-Administered LT Vaccine Patch With an LT Vaccine Patch Administered by a Clinician</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercell USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercell USA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the immune responses achieved following self-administered heat-labile enterotoxin
      of E. coli (LT) vaccination by transcutaneous immunization compared to the immune responses
      achieved by clinician-administered vaccination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GMTs After a Self-administered LT Vaccine Patch (In-clinic or Away From Clinic) Compared to a Clinician-administered LT Vaccine Patch.</measure>
    <time_frame>Day 0, Day 14, Day 21, Day 28, Day 35, Day 194</time_frame>
    <description>The primary endpoint of this trial was to compare the immunogenicity (i.e., GMTs, GMFRs and seroconversion rates for LT IgG and IgA) of subject self-administered [second] vaccination with clinician-administered [second] vaccination, using the deltoid/thigh (Vaccination 1/Vaccination 2) treatment regimen.
GMT: geometric mean titer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMFR After a Self-administered LT Vaccine Patch (In-clinic or Away From Clinic) Compared to a Clinician-administered LT Vaccine Patch.</measure>
    <time_frame>Day 14, Day 21, Day 28, Day 35, Day 194</time_frame>
    <description>The primary endpoint of this trial was to compare the immunogenicity (i.e., GMTs, GMFRs and seroconversion rates for LT IgG and IgA) of subject self-administered [second] vaccination with clinician-administered [second] vaccination, using the deltoid/thigh (Vaccination 1/Vaccination 2) treatment regimen.
GMFR: geometric mean fold ratio GMFRs relative to the baseline titer were determined for LT IgG and LT IgA at each post-baseline time point. All GMFRs were based on log10-transformed data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion After a Self-administered LT Vaccine Patch (In-clinic or Away From Clinic) Compared to a Clinician-administered LT Vaccine Patch.</measure>
    <time_frame>Day 14, Day 21, Day 28, Day 35, Day 194</time_frame>
    <description>The primary endpoint of this trial was to compare the immunogenicity (i.e., GMTs, GMFRs and seroconversion rates (SCR) for LT IgG and IgA) of subject self-administered [second] vaccination with clinician-administered [second] vaccination, using the deltoid/thigh (Vaccination 1/Vaccination 2) treatment regimen.
seroconversion (SC): two-fold or greater rise in titer relative to Day 0 for LT IgG and a four-fold or greater rise in titer relative to Day 0 for LT IgA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Self-administered LT Vaccine Patch and Comparison to the Clinician-administered LT Vaccine Patch</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Immunogenicity for Deltoid/Thigh (Prime/Boost) Versus Deltoid/Deltoid Administered LT Vaccine.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Evaluation of Immunogenicity for Self-administration In-clinic Compared to Self-administration Away From the Clinic.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Prevention of Travelers' Diarrhea</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT patch on the left deltoid by a Clinician on Day 0. Two weeks later will have the same treatment repeated on the right deltoid by the clinician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 subjects will be pretreated with SPS:Buffer and a patch containing 37.5ug will be applied on the left deltoid by the Clinician. Fourteen days later, the same procedure will occur on the left thigh by the clinician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT on the left deltoid by the clinician. Two weeks later subject will have the same treatment repeated by self-application in the clinic on the left thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 subjects will have skin prepared using SPS:Buffer and will have 37.5ug LT patch on the left deltoid by a clinician. Two weeks later subjects will have the same treatment repeated by self-application at home on the left thigh.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>heat-labile enterotoxin of E. coli (LT)</intervention_name>
    <description>37.5ug patch applied on either the deltoid or the thigh</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>TD Vaccine System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following inclusion criteria to be eligible to participate in
        the study:

          -  Healthy adult males or females 18-64 years of age with signed Informed Consent.

          -  Women who are not post-menopausal or surgically sterile must have a negative serum or
             urine pregnancy test at screening and within 24 hours of each vaccination with
             understanding (through Informed Consent process) to not become pregnant over the
             duration of the study, and must agree to employ an effective form of birth control for
             the duration of the study. Acceptable forms of birth control are: abstinence, hormonal
             contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives
             (condom or diaphragm, with spermicide), and IUD.

        Exclusion Criteria:

        Subjects meeting any of the following criteria are not eligible for participation in the
        study:

          -  Laboratory abnormalities [as determined by the Toxicity Grading Scale (grade 1-4)] at
             laboratory screening

          -  Abnormalities at physical examination [as determined by the Toxicity Grading Scale
             (grade 1-4)]

          -  Known allergies to any component of the vaccine

          -  Known allergies to adhesives

          -  Participated in research involving investigational product within 30 days before
             planned date of first vaccination

          -  Donated blood or blood products such as plasma within the past 30 days

          -  Ever received investigational enterotoxigenic E. coli, LT, or LT (R192G) or NasalFlu,
             Berna Biotech, Ltd

          -  Ever received cholera toxin or vaccine (e.g. Orochol™, Dukoral™)

          -  History of traveler's diarrhea in the previous two years

          -  History of abdominal surgery (excluding C-Section, hysterectomy, cosmetic surgery,
             liposuction, appendectomy, cholecystectomy, ventral hernia repair, and other surgeries
             not pertaining to gastrointestinal problems) or history of, or recent acute
             gastrointestinal (GI) illness

          -  Positive serology for HIV-1, HIV-2, HBsAg, or HCV

          -  Medical history of acute or chronic skin disease at vaccination area(s)

          -  Active skin allergy

          -  Signs of acute skin infection, sunburn or skin abnormalities at the vaccination
             area(s) including fungal infections, severe acne, or active contact dermatitis, or a
             history of keloid formation

          -  Excessively hirsute at the vaccination area(s) that would interfere with patch
             adhesion in the opinion of the Investigator

          -  Visible tattoos or marks (tattoos/scars) at the vaccination area(s) that would prevent
             appropriate dermatologic monitoring of the vaccination site(s)

          -  Fever greater than or equal to 38.0°C (100.4°F) at the time of planned vaccination

          -  Women who are pregnant or breastfeeding

          -  Acute illness at screening or at baseline; or

          -  Employee of the investigational site.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Forte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arkansas Medical Research Testing</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Medical Research Testing</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2007</study_first_posted>
  <results_first_submitted>January 30, 2014</results_first_submitted>
  <results_first_submitted_qc>March 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2014</results_first_posted>
  <last_update_submitted>March 17, 2014</last_update_submitted>
  <last_update_submitted_qc>March 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clinician Administered (Deltoid)</title>
          <description>40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT patch on the left deltoid by a Clinician on Day 0. Two weeks later will have the same treatment repeated on the right deltoid by the clinician
heat-labile enterotoxin of E. coli (LT): 37.5ug patch applied on either the deltoid or the thigh</description>
        </group>
        <group group_id="P2">
          <title>Clinician Administered (Thigh)</title>
          <description>40 subjects will be pretreated with SPS:Buffer and a patch containing 37.5ug will be applied on the left deltoid by the Clinician. Fourteen days later, the same procedure will occur on the left thigh by the clinician.
heat-labile enterotoxin of E. coli (LT): 37.5ug patch applied on either the deltoid or the thigh</description>
        </group>
        <group group_id="P3">
          <title>Self Administered (In-clinic)</title>
          <description>40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT on the left deltoid by the clinician. Two weeks later subject will have the same treatment repeated by self-application in the clinic on the left thigh.
heat-labile enterotoxin of E. coli (LT): 37.5ug patch applied on either the deltoid or the thigh</description>
        </group>
        <group group_id="P4">
          <title>Self Administered (Non-clinic)</title>
          <description>40 subjects will have skin prepared using SPS:Buffer and will have 37.5ug LT patch on the left deltoid by a clinician. Two weeks later subjects will have the same treatment repeated by self-application at home on the left thigh.
heat-labile enterotoxin of E. coli (LT): 37.5ug patch applied on either the deltoid or the thigh</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clinician Administered (Deltoid)</title>
          <description>40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT patch on the left deltoid by a Clinician on Day 0. Two weeks later will have the same treatment repeated on the right deltoid by the clinician
heat-labile enterotoxin of E. coli (LT): 37.5ug patch applied on either the deltoid or the thigh</description>
        </group>
        <group group_id="B2">
          <title>Clinician Administered (Thigh)</title>
          <description>40 subjects will be pretreated with SPS:Buffer and a patch containing 37.5ug will be applied on the left deltoid by the Clinician. Fourteen days later, the same procedure will occur on the left thigh by the clinician.
heat-labile enterotoxin of E. coli (LT): 37.5ug patch applied on either the deltoid or the thigh</description>
        </group>
        <group group_id="B3">
          <title>Self Administered (In-clinic)</title>
          <description>40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT on the left deltoid by the clinician. Two weeks later subject will have the same treatment repeated by self-application in the clinic on the left thigh.
heat-labile enterotoxin of E. coli (LT): 37.5ug patch applied on either the deltoid or the thigh</description>
        </group>
        <group group_id="B4">
          <title>Self Administered (Non-clinic)</title>
          <description>40 subjects will have skin prepared using SPS:Buffer and will have 37.5ug LT patch on the left deltoid by a clinician. Two weeks later subjects will have the same treatment repeated by self-application at home on the left thigh.
heat-labile enterotoxin of E. coli (LT): 37.5ug patch applied on either the deltoid or the thigh</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="12.21"/>
                    <measurement group_id="B2" value="35.0" spread="11.10"/>
                    <measurement group_id="B3" value="38.1" spread="11.18"/>
                    <measurement group_id="B4" value="34.1" spread="11.18"/>
                    <measurement group_id="B5" value="36.0" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>GMTs After a Self-administered LT Vaccine Patch (In-clinic or Away From Clinic) Compared to a Clinician-administered LT Vaccine Patch.</title>
        <description>The primary endpoint of this trial was to compare the immunogenicity (i.e., GMTs, GMFRs and seroconversion rates for LT IgG and IgA) of subject self-administered [second] vaccination with clinician-administered [second] vaccination, using the deltoid/thigh (Vaccination 1/Vaccination 2) treatment regimen.
GMT: geometric mean titer</description>
        <time_frame>Day 0, Day 14, Day 21, Day 28, Day 35, Day 194</time_frame>
        <population>intent to treat population = primary analysis population; defined as all study subjects who were consented, randomized, and had a baseline serology</population>
        <group_list>
          <group group_id="O1">
            <title>Clinician Administered (Deltoid/ Thigh)</title>
            <description>st vaccination: administered by clinician; location: deltoid
nd vaccination: administered by clinician; location: thigh</description>
          </group>
          <group group_id="O2">
            <title>Self Administered (In-clinic &amp; Non-clinic)</title>
            <description>st vaccination: administered by clinician; location: deltoid
nd vaccination: self-administration either in-clinic or away from the clinic; location: thigh</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs After a Self-administered LT Vaccine Patch (In-clinic or Away From Clinic) Compared to a Clinician-administered LT Vaccine Patch.</title>
          <description>The primary endpoint of this trial was to compare the immunogenicity (i.e., GMTs, GMFRs and seroconversion rates for LT IgG and IgA) of subject self-administered [second] vaccination with clinician-administered [second] vaccination, using the deltoid/thigh (Vaccination 1/Vaccination 2) treatment regimen.
GMT: geometric mean titer</description>
          <population>intent to treat population = primary analysis population; defined as all study subjects who were consented, randomized, and had a baseline serology</population>
          <units>geometric mean titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LT IgG GMTs - Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="362" lower_limit="264" upper_limit="496"/>
                    <measurement group_id="O2" value="442" lower_limit="354" upper_limit="552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgG GMTs - Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1974" lower_limit="1196" upper_limit="3258"/>
                    <measurement group_id="O2" value="2896" lower_limit="2032" upper_limit="4127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgG GMTs - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4747" lower_limit="3232" upper_limit="6973"/>
                    <measurement group_id="O2" value="7545" lower_limit="5759" upper_limit="9886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgG GMTs - Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11153" lower_limit="8255" upper_limit="15068"/>
                    <measurement group_id="O2" value="12180" lower_limit="9832" upper_limit="15089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgG GMTs - Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12165" lower_limit="9320" upper_limit="15877"/>
                    <measurement group_id="O2" value="12745" lower_limit="10519" upper_limit="15442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgG GMTs - Day 194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4997" lower_limit="3753" upper_limit="6654"/>
                    <measurement group_id="O2" value="6035" lower_limit="4917" upper_limit="7409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA GMTs - Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="41" upper_limit="69"/>
                    <measurement group_id="O2" value="53" lower_limit="44" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA GMTs - Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218" lower_limit="142" upper_limit="335"/>
                    <measurement group_id="O2" value="365" lower_limit="270" upper_limit="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA GMTs - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430" lower_limit="309" upper_limit="598"/>
                    <measurement group_id="O2" value="639" lower_limit="507" upper_limit="806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA GMTs - Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632" lower_limit="462" upper_limit="864"/>
                    <measurement group_id="O2" value="768" lower_limit="615" upper_limit="960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA GMTs - Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="548" lower_limit="397" upper_limit="757"/>
                    <measurement group_id="O2" value="712" lower_limit="564" upper_limit="898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA GMTs - Day 194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254" lower_limit="190" upper_limit="341"/>
                    <measurement group_id="O2" value="287" lower_limit="233" upper_limit="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of Self-administered LT Vaccine Patch and Comparison to the Clinician-administered LT Vaccine Patch</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Immunogenicity for Deltoid/Thigh (Prime/Boost) Versus Deltoid/Deltoid Administered LT Vaccine.</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Evaluation of Immunogenicity for Self-administration In-clinic Compared to Self-administration Away From the Clinic.</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GMFR After a Self-administered LT Vaccine Patch (In-clinic or Away From Clinic) Compared to a Clinician-administered LT Vaccine Patch.</title>
        <description>The primary endpoint of this trial was to compare the immunogenicity (i.e., GMTs, GMFRs and seroconversion rates for LT IgG and IgA) of subject self-administered [second] vaccination with clinician-administered [second] vaccination, using the deltoid/thigh (Vaccination 1/Vaccination 2) treatment regimen.
GMFR: geometric mean fold ratio GMFRs relative to the baseline titer were determined for LT IgG and LT IgA at each post-baseline time point. All GMFRs were based on log10-transformed data.</description>
        <time_frame>Day 14, Day 21, Day 28, Day 35, Day 194</time_frame>
        <population>intent to treat population = primary analysis population; defined as all study subjects who were consented, randomized, and had a baseline serology</population>
        <group_list>
          <group group_id="O1">
            <title>Clinician Administered (Deltoid/ Thigh)</title>
            <description>st vaccination: administered by clinician; location: deltoid
nd vaccination: administered by clinician; location: thigh</description>
          </group>
          <group group_id="O2">
            <title>Self Administered (In-clinic &amp; Non-clinic)</title>
            <description>st vaccination: administered by clinician; location: deltoid
nd vaccination: self-administration either in-clinic or away from the clinic; location: thigh</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR After a Self-administered LT Vaccine Patch (In-clinic or Away From Clinic) Compared to a Clinician-administered LT Vaccine Patch.</title>
          <description>The primary endpoint of this trial was to compare the immunogenicity (i.e., GMTs, GMFRs and seroconversion rates for LT IgG and IgA) of subject self-administered [second] vaccination with clinician-administered [second] vaccination, using the deltoid/thigh (Vaccination 1/Vaccination 2) treatment regimen.
GMFR: geometric mean fold ratio GMFRs relative to the baseline titer were determined for LT IgG and LT IgA at each post-baseline time point. All GMFRs were based on log10-transformed data.</description>
          <population>intent to treat population = primary analysis population; defined as all study subjects who were consented, randomized, and had a baseline serology</population>
          <units>geometric mean fold ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LT IgG GMFR - Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgG GMFR - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="9" upper_limit="20"/>
                    <measurement group_id="O2" value="17" lower_limit="13" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgG GMFR - Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="22" upper_limit="44"/>
                    <measurement group_id="O2" value="28" lower_limit="21" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgG GMFR - Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="23" upper_limit="49"/>
                    <measurement group_id="O2" value="29" lower_limit="22" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgG GMFR - Day 194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O2" value="14" lower_limit="11" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA GMFR - Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA GMFR - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="5" upper_limit="11"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA GMFR - Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="9" upper_limit="16"/>
                    <measurement group_id="O2" value="15" lower_limit="12" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA GMFR - Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7" upper_limit="15"/>
                    <measurement group_id="O2" value="13" lower_limit="11" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA GMFR - Day 194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion After a Self-administered LT Vaccine Patch (In-clinic or Away From Clinic) Compared to a Clinician-administered LT Vaccine Patch.</title>
        <description>The primary endpoint of this trial was to compare the immunogenicity (i.e., GMTs, GMFRs and seroconversion rates (SCR) for LT IgG and IgA) of subject self-administered [second] vaccination with clinician-administered [second] vaccination, using the deltoid/thigh (Vaccination 1/Vaccination 2) treatment regimen.
seroconversion (SC): two-fold or greater rise in titer relative to Day 0 for LT IgG and a four-fold or greater rise in titer relative to Day 0 for LT IgA</description>
        <time_frame>Day 14, Day 21, Day 28, Day 35, Day 194</time_frame>
        <population>intent to treat population = primary analysis population; defined as all study subjects who were consented, randomized, and had a baseline serology</population>
        <group_list>
          <group group_id="O1">
            <title>Clinician Administered (Deltoid/ Thigh)</title>
            <description>st vaccination: administered by clinician; location: deltoid
nd vaccination: administered by clinician; location: thigh</description>
          </group>
          <group group_id="O2">
            <title>Self Administered (In-clinic &amp; Non-clinic)</title>
            <description>st vaccination: administered by clinician; location: deltoid
nd vaccination: self-administration either in-clinic or away from the clinic; location: thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion After a Self-administered LT Vaccine Patch (In-clinic or Away From Clinic) Compared to a Clinician-administered LT Vaccine Patch.</title>
          <description>The primary endpoint of this trial was to compare the immunogenicity (i.e., GMTs, GMFRs and seroconversion rates (SCR) for LT IgG and IgA) of subject self-administered [second] vaccination with clinician-administered [second] vaccination, using the deltoid/thigh (Vaccination 1/Vaccination 2) treatment regimen.
seroconversion (SC): two-fold or greater rise in titer relative to Day 0 for LT IgG and a four-fold or greater rise in titer relative to Day 0 for LT IgA</description>
          <population>intent to treat population = primary analysis population; defined as all study subjects who were consented, randomized, and had a baseline serology</population>
          <units>percentage of study participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LT IgG SCR - Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="48" upper_limit="79"/>
                    <measurement group_id="O2" value="73" lower_limit="61" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgG SCR - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="79" upper_limit="98"/>
                    <measurement group_id="O2" value="98" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgG SCR - Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgG SCR - Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgG SCR - Day 194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA SCR - Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="32" upper_limit="64"/>
                    <measurement group_id="O2" value="59" lower_limit="47" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA SCR - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="52" upper_limit="83"/>
                    <measurement group_id="O2" value="85" lower_limit="75" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA SCR - Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="67" upper_limit="93"/>
                    <measurement group_id="O2" value="90" lower_limit="81" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA SCR - Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="64" upper_limit="91"/>
                    <measurement group_id="O2" value="87" lower_limit="77" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LT IgA SCR - Day 194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="52" upper_limit="83"/>
                    <measurement group_id="O2" value="62" lower_limit="50" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Clinician Administered (Deltoid)</title>
          <description>40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT patch on the left deltoid by a Clinician on Day 0. Two weeks later will have the same treatment repeated on the right deltoid by the clinician
heat-labile enterotoxin of E. coli (LT): 37.5ug patch applied on either the deltoid or the thigh</description>
        </group>
        <group group_id="E2">
          <title>Clinician Administered (Thigh)</title>
          <description>40 subjects will be pretreated with SPS:Buffer and a patch containing 37.5ug will be applied on the left deltoid by the Clinician. Fourteen days later, the same procedure will occur on the left thigh by the clinician.
heat-labile enterotoxin of E. coli (LT): 37.5ug patch applied on either the deltoid or the thigh</description>
        </group>
        <group group_id="E3">
          <title>Self Administered (In-clinic)</title>
          <description>40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT on the left deltoid by the clinician. Two weeks later subject will have the same treatment repeated by self-application in the clinic on the left thigh.
heat-labile enterotoxin of E. coli (LT): 37.5ug patch applied on either the deltoid or the thigh</description>
        </group>
        <group group_id="E4">
          <title>Self Administered (Non-clinic)</title>
          <description>40 subjects will have skin prepared using SPS:Buffer and will have 37.5ug LT patch on the left deltoid by a clinician. Two weeks later subjects will have the same treatment repeated by self-application at home on the left thigh.
heat-labile enterotoxin of E. coli (LT): 37.5ug patch applied on either the deltoid or the thigh</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Brugada syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Application site discoloration</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Application site edema</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Application site excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Application site scab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Red blood cells in urine</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head Clinical Development</name_or_title>
      <organization>Valneva Austria GmbH</organization>
      <phone>0043120620 ext 0</phone>
      <email>info@valneva.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

